Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection

Next Previous
Trial Profile

A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors CytoDyn

Most Recent Events

  • 12 Apr 2022 According to CytoDyn Media Release, results assessing virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antiretroviral therapy (ART) and in ART-naive acutely CCR5-tropic SHIV infected rhesus macaques (n = 4) using data from 2 trials (NCT02175680 and NCT02355184) published as peer reviewed paper in the open-access journal PLOS Pathogens.
  • 12 Apr 2022 Results assessing virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antiretroviral therapy (ART) and in ART-naive acutely CCR5-tropic SHIV infected rhesus macaques (n = 4) using data from 2 trials (NCT02175680 and NCT02355184) published in the CytoDyn Media Release
  • 20 Apr 2018 Results of long-term safety and efficacy data from two phase IIb studies published in the HIV Clinical Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top